The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...

ACL Digital will also be able to drive digital transformation for biotech, pharmaceutical and medical device companies. Credit: tilialucida / Shutterstock.com. ACL Digital has acquired US-based ...

On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing correction in a Phase I trial.

US pharma giant Eli Lilly has axed its Phase IIb trial of tirzepatide and bimagrumab, which was exploring the efficacy and safety of the combination in patients with obesity who have comborbid type 2 ...

Anebulo prioritised developing selonabant IV formulation as a potential treatment for paediatric patients with acute cannabis toxicity. Credit: murat photographer / Shutterstock.com. Anebulo ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of trial processes.

atai Life Sciences and Beckley Psytech’s psychedelic has demonstrated significant efficacy in a Phase IIa trial, meaning the companies will now progress BPL-003 (intranasal mebufotenin benzoate) to ...

Tom Gottschalk, Prasun Mishra, and Luiz Barberini expounded the foundational role AI and blockchain will play in the future of clinical trials. Credit: Athanasios Psimadis/ Arena International Events ...

MBX Biosciences announced the Phase II data from the Avail trial. Image credit: Poetra.RH / Shutterstock.com MBX Biosciences is advancing its hypoparathyroidism drug after 63% of patients achieved the ...